- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01521611
Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy
Radiolabelled Anti-CD66 Monoclonal Antibody in the Conditioning Regimen Prior to Haematopoietic Stem Cell Transplantation: Phase I Study in Patients With Poor-risk Disease.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The aim of this clinical research study is to establish whether a radiolabelled antibody can be used to safely deliver radiotherapy to the bone marrow prior to stem cell transplantation for haematological malignancies.
With current chemotherapy regimens 60-90% of adult patients with acute leukaemia (AML and ALL) achieve a complete remission. However in a significant proportion of these patients the disease will recur. Although allogeneic and autologous bone marrow or peripheral blood haematopoietic stem cell transplantation (HSCT) are established as effective treatment options for haematological malignancies, resulting in long term disease free survival in a significant proportion of patients, the results of transplantation for patients with poor risk disease are disappointing. Further intensification of the treatment used prior to transplantation has been shown to reduce the risk of relapse, but the toxicity of the drugs or external beam radiotherapy causes an increase in transplant related deaths. The introduction of reduced intensity conditioning protocols allows the use of HSCT for older patients or those with significant additional medical problems but retrospective analysis indicates an increased rate of relapse. This is the 'Transplantation dilemma' - how to reduce the risk of disease relapse by intensifying therapy, but without an increase in toxicity to other organs causing an increase in transplant related deaths in remission.
Normal haematopoietic tissue and the malignant cells arising from it are very radiosensitive. Theoretically intensification of the conditioning therapy, particularly total body irradiation (TBI), prior to transplantation could increase tumour reduction leading to improved disease free survival rates for patients with poor risk disease. Targeted radiotherapy could allow treatment intensification without the toxicity to non-haematological tissues. In addition, the continuous, low dose rate delivered by the natural decay of a targeted radionuclide may have a greater destructive effect upon tumour cells than single dose or fractionated external beam radiation.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
- Fase 1
Contactos e Locais
Locais de estudo
-
-
-
London, Reino Unido
- Royal Free Hospital and University College London
-
-
Hampshire
-
Southampton, Hampshire, Reino Unido, SO16 6YD
- Southampton University Hospitals NHS Trust
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- An underlying haematological malignancy including acute myeloid leukaemia in first complete remission (CR1) but with poor prognostic features or in >CR1 or in relapse; acute lymphoblastic leukaemia; transformed myelodysplasia, chronic myeloid leukaemia (accelerated phase or blast transformation, poor response or intolerance of tyrosine kinase inhibitors), myeloma. Patients may be in remission, partial remission or relapse.
- No concurrent or recent (within 3 weeks) chemotherapy for the underlying haematological condition
- For patients with relapsed leukaemia, bone marrow (BM) blasts must represent < 20% of BM nucleated cells.
- Although the BM remission status is not important, patients must have cellularity > 10%.
- As malignant plasma cells may or may not express CD66 antigens, patients with myeloma must have less than 30% plasma cells (as a percentage of total nucleated cells) in the BM at the time of the study.
- Age = or >18 yrs.
- WHO performance status of 0, 1 or 2 (Appendix 5).
- Predicted life-expectancy of greater than four months.
- Patients must be negative for human anti-mouse antibodies (HAMA).
Peripheral blood counts:
Wbc < 30 x 10e9/l (absolute neutrophil count >0.5 x 10e9/L) platelets > 50 x 10e9/l (platelet support is permitted)
Biochemical indices:
Plasma creatinine < 120 micromol/l (or creatinine clearance or Ethylene diamine tetra acetic acid (EDTA) clearance > 50 ml/min) Plasma bilirubin < 30 micromol/l Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) no more than 2.5 x upper limit of the normal range.
- Patient must be able to provide written informed consent.
Exclusion Criteria:
- Any serious intercurrent disease.
- Patients with BM cellularity < 10%.
- History of atopic asthma, eczema or allergy to rodent protein, confirmed history of severe allergic reactions to penicillin or streptomycin.
- Positive Human anti-murine antibodies (HAMA).
- Patients unable to provide informed consent or who are unable to co-operate for reasons of poor mental or physical health.
- Pregnancy
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Targeted radiotherapy
Patients receive therapy with an yttrium-90 labelled anti-CD66 following favourable dosimetry with the same antibody radiolabelled with indium-111.
|
Yttrium-90 labelled anti-CD66 monoclonal antibody.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Toxicities related to radiolabelled antibody.
Prazo: Up to 1 year post transplant World Health Organisation (WHO) toxicity criteria
|
To determine the maximum tolerated dose (MTD) of targeted radiotherapy delivered by a murine anti-CD66 monoclonal antibody radiolabelled with yttrium-90 (Y-90) and determine the dose-limiting toxicity (DLT) in patients with haematological malignancies who are undergoing haematopoietic stem cell transplantation. Toxicities are assessed using WHO Toxicity Scale with 28 parameters. |
Up to 1 year post transplant World Health Organisation (WHO) toxicity criteria
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Dosimetry model
Prazo: 5 days post infusion of an Indium-111 radiolabelled anti-CD66
|
Dosimetry is determined by whole body and SPECT-CT of the thorax and abdomen on days 1, 2, 4 and 5 post infusion of an indium-111 radiolabelled anti-CD66.
Dosimetry determines whether patients proceed to therapy with the yttrium-90 labelled anti-CD66.
|
5 days post infusion of an Indium-111 radiolabelled anti-CD66
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Kim H Orchard, MBBS PhD, University Hospital Southampton NHS Foundation Trust
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- RHMCAN0227
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Targeted radiotherapy
-
Impact Biotech LtdImpact biotech Ltd.Ativo, não recrutandoAdenocarcinoma de pâncreas irressecável localmente avançadoEstados Unidos
-
University of VirginiaConcluídoLesão da medula espinal | Úlceras de pressãoEstados Unidos
-
Ottawa Hospital Research InstituteRescindidoCarcinoma Pancreático Não RessecávelCanadá
-
Endourage, LLCRecrutamentoLongo COVID | Longo Covid19 | Pós-Agudo COVID-19 | Longo Curso COVID | Longo Curso COVID-19 | Síndrome Pós-Aguda de COVID-19Estados Unidos
-
Impact Biotech LtdImpact biotech Ltd.Ainda não está recrutandoTumor Pulmonar Periférico